Regeneron Ventures

Normunity is a biotechnology company focused on developing precision immuno-oncology medicines, specifically a new class known as immune normalizers. These medicines aim to target novel mechanisms that enhance the body’s natural immune response against cancer. In collaboration with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is researching newly-discovered mechanisms of immune disruption in cancer, utilizing proprietary discovery platforms to explore the intricate interactions between cancer and the immune system. The company is advancing a pipeline of immune normalizers, which includes initial drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune function in cancer. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the epigenome, the company aims to create new pathways for treatment without making changes to the DNA sequence itself. This approach allows for the potential development of therapies for complex and widespread medical conditions, positioning Tune Therapeutics at the forefront of advancements in the field of epigenetics.

Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing effective and accessible immune cell therapies, primarily targeting cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create a new paradigm for discovering and developing immune cell therapies. ArsenalBio's innovative approach aims to enhance the efficacy and safety of T-cell therapies while reducing costs for providers and broadening patient access. By employing a full-stack research and development engine, ArsenalBio generates multifunctional T-cell medicines through the precise insertion of large synthetic DNA sequences, enabling clinicians to utilize next-generation autologous T-cell therapies to combat cancer more effectively.